What is Zacks Research’s Estimate for FOLD Q1 Earnings?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Research analysts at Zacks Research issued their Q1 2025 EPS estimates for Amicus Therapeutics in a note issued to investors on Tuesday, April 1st. Zacks Research analyst R. Department anticipates that the biopharmaceutical company will earn ($0.01) per share for the quarter. The consensus estimate for Amicus Therapeutics’ current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics’ Q3 2026 earnings at $0.11 EPS.

A number of other equities analysts also recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Finally, Wells Fargo & Company dropped their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Stock Up 0.5 %

FOLD stock opened at $7.99 on Thursday. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of -44.39, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The business’s 50 day moving average price is $9.19 and its two-hundred day moving average price is $9.90. Amicus Therapeutics has a fifty-two week low of $7.85 and a fifty-two week high of $12.65.

Institutional Investors Weigh In On Amicus Therapeutics

Hedge funds have recently made changes to their positions in the company. Virtus Fund Advisers LLC purchased a new stake in shares of Amicus Therapeutics during the 4th quarter worth approximately $29,000. Covestor Ltd lifted its position in Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 2,312 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Amicus Therapeutics in the 3rd quarter worth $55,000. GF Fund Management CO. LTD. bought a new stake in shares of Amicus Therapeutics in the 4th quarter worth about $59,000. Finally, R Squared Ltd bought a new position in shares of Amicus Therapeutics in the 4th quarter valued at about $79,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.